The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease
Open accessAbstract
Alzheimer disease (AD) is the most common cause of dementia in adults. The current therapy for AD has only moderate efficacy in controlling symptoms, and it does not cure the disease. Recent studies have suggested that abnormal hyperphosphorylation of tau in the brain plays a vital role in the molecular pathogenesis of AD and in neurodegeneration. This article reviews the current advances in understanding of tau protein, regulation of tau phosphorylation, and the role of its abnormal hyperphosphorylation in neurofibrillary degeneration. Furthermore, several therapeutic strategies for treating AD on the basis of the important role of tau hyperphosphorylation in the pathogenesis of the disease are described. These strategies include (1) inhibition of glycogen synthase kinase-3beta (GSK-3beta), cyclin-dependent kinase 5 (cdk5), and other tau kinases; (2) restoration of PP2A activity; and (3) targeting tau O-GlcNAcylation. Development of drugs on the basis of these strategies is likely to lead to disease-modifying therapies for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Self-citationA protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Observations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,778
Self-citationConversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., & Tsai, L.-H. (1999) · Nature · doi:10.1038/45159 · Cited by 1,545
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Phosphorylation affects the ability of tau protein to promote microtubule assembly.
Lindwall, G., & Cole, R. D. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42989-9 · Cited by 901
Stamer, K., Vogel, R., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200108057 · Cited by 885
Alonso, A. D. C., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0796-783 · Cited by 859
Self-citationEbneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., Mandelkow, E.-M., & Mandelkow, E. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.3.777 · Cited by 820
GSK3 inhibitors: development and therapeutic potential
Cohen, P., & Goedert, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1415 · Cited by 790
Köpke, E., Tung, Y. C., Shaikh, S., Alonso, A. C., Iqbal, K., & Grundke-Iqbal, I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80536-5 · Cited by 779
Self-citationO-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775
Self-citationAltered microtubule organization in small-calibre axons of mice lacking tau protein
Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., Sato-Yoshitake, R., Takei, Y., Noda, T., & Hirokawa, N. (1994) · Nature · doi:10.1038/369488a0 · Cited by 760
Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04391.x · Cited by 759
Self-citationRole of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease.
Alonso, A. C., Zaidi, T., Grundke-Iqbal, I., & Iqbal, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5562 · Cited by 738
Self-citationPhysical and chemical properties of purified tau factor and the role of tau in microtubule assembly
Cleveland, D. W., Hwo, S.-Y., & Kirschner, M. W. (1977) · Journal of Molecular Biology · doi:10.1016/0022-2836(77)90214-5 · Cited by 730
De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 729
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Developmentally regulated expression of specific tau sequences
Kosik, K. S., Orecchio, L. D., Bakalis, S., & Neve, R. L. (1989) · Neuron · doi:10.1016/0896-6273(89)90077-9 · Cited by 601
Pharmacological inhibitors of glycogen synthase kinase 3
MEIJER, L., FLAJOLET, M., & GREENGARD, P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.006 · Cited by 584
Matsuo, E. S., Shin, R.-W., Billingsley, M. L., Van deVoorde, A., O'Connor, M., Trojanowski, J. Q., & Lee, V. M. Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90264-x · Cited by 576
Neve, R. L., Harris, P., Kosik, K. S., Kurnit, D. M., & Donlon, T. A. (1986) · Molecular Brain Research · doi:10.1016/0169-328x(86)90033-1 · Cited by 565
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration
Wang, J., Grundke‐Iqbal, I., & Iqbal, K. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05226.x · Cited by 553
Self-citationPharmacological inhibitors of cyclin-dependent kinases
Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537
Phosphoprotein Phosphatase Activities in Alzheimer Disease Brain
Gong, C., Singh, T. J., Grundke‐Iqbal, I., & Iqbal, K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03603.x · Cited by 527
Self-citationMolecular Targets of Lithium Action
Phiel, C. J., & Klein, P. S. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.789 · Cited by 515
The microtubule binding domain of tau protein
Lee, G., Neve, R. L., & Kosik, K. S. (1989) · Neuron · doi:10.1016/0896-6273(89)90050-0 · Cited by 500
Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium
Ryves, W. J., & Harwood, A. J. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4169 · Cited by 493
Simpson, I. A., Chundu, K. R., Davies‐Hill, T., Honer, W. G., & Davies, P. (1994) · Annals of Neurology · doi:10.1002/ana.410350507 · Cited by 490
Craft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487
The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A
Li, M., Makkinje, A., & Damuni, Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11059 · Cited by 479
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
Hanger, D. P., Byers, H. L., Wray, S., Leung, K.-Y., Saxton, M. J., Seereeram, A., Reynolds, C. H., Ward, M. A., & Anderton, B. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703269200 · Cited by 455
Phosphatase Activity Toward Abnormally Phosphorylated τ: Decrease in Alzheimer Disease Brain
Gong, C., Shaikh, S., Wang, J., Zaidi, T., Grundke‐Iqbal, I., & Iqbal, K. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65020732.x · Cited by 438
Self-citationPost-translational modifications of tau protein in Alzheimer’s disease
Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437
Self-citationAlonso, A. D. C., Grundke-Iqbal, I., Barra, H. S., & Iqbal, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.298 · Cited by 437
Self-citationInhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium
Zhang, F., Phiel, C. J., Spece, L., Gurvich, N., & Klein, P. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212635200 · Cited by 435
Defects in Axonal Elongation and Neuronal Migration in Mice with Disrupted tau and map1b Genes
Takei, Y., Teng, J., Harada, A., & Hirokawa, N. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.150.5.989 · Cited by 408
Gong, C.-X., Lidsky, T., Wegiel, J., Zuck, L., Grundke-Iqbal, I., & Iqbal, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5535 · Cited by 405
Self-citationGoode, B., & Feinstein, S. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.5.769 · Cited by 399
GSK-3 is essential in the pathogenesis of Alzheimer's disease
Takashima, A. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s335 · Cited by 396
Liu, Y., Liu, F., Iqbal, K., Grundke-Iqbal, I., & Gong, C.-X. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.12.035 · Cited by 394
Self-citationSontag, E., Nunbhakdi-Craig, V., Lee, G., Bloom, G. S., & Mumby, M. C. (1996) · Neuron · doi:10.1016/s0896-6273(00)80250-0 · Cited by 391
Tau proteins: the molecular structure and mode of binding on microtubules.
Hirokawa, N., Shiomura, Y., & Okabe, S. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.4.1449 · Cited by 389
Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65533-2 · Cited by 385
O-GlcNAcase Uses Substrate-assisted Catalysis
Macauley, M. S., Whitworth, G. E., Debowski, A. W., Chin, D., & Vocadlo, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413819200 · Cited by 377
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein
Probst, A., Götz, J., Wiederhold, K. H., Tolnay, M., Mistl, C., Jaton, A. L., Hong, M., Ishihara, T., Lee, V. M.-Y., Trojanowski, J. Q., et al. (2000) · Acta Neuropathologica · doi:10.1007/s004010051148 · Cited by 365
The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine
Arnold, C. S., Johnson, G. W., Cole, R. N., Dong, D. L.-Y., Lee, M., & Hart, G. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28741 · Cited by 361
Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations
Alonso, A. D. C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., & Iqbal, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405131200 · Cited by 329
Self-citationC-terminal inhibition of tau assembly in vitro and in Alzheimer’s disease
Abraha, A., Ghoshal, N., Gamblin, T. C., Cryns, V., Berry, R. W., Kuret, J., & Binder, L. I. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.21.3737 · Cited by 325
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice
Pedersen, W. A., McMillan, P. J., Kulstad, J. J., Leverenz, J. B., Craft, S., & Haynatzki, G. R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.018 · Cited by 322
Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation
Cash, A. D., Aliev, G., Siedlak, S. L., Nunomura, A., Fujioka, H., Zhu, X., Raina, A. K., Vinters, H. V., Tabaton, M., Johnson, A. B., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64296-4 · Cited by 307
Ferrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribe, E., Dalfo, E., & Avila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 304
A Gene Expression Profile of Alzheimer's Disease
Loring, J. F., Wen, X., Lee, J. M., Seilhamer, J., & Somogyi, R. (2001) · DNA and Cell Biology · doi:10.1089/10445490152717541 · Cited by 300
Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608485200 · Cited by 283
Tau phosphorylation and aggregation in Alzheimer's disease pathology
Avila, J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.02.067 · Cited by 282
PP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus
Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7630 · Cited by 281
Alafuzoff, I., Iqbal, K., Friden, H., Adolfsson, R., & Winblad, B. (1987) · Acta Neuropathologica · doi:10.1007/bf00688184 · Cited by 266
Self-citationPlanel, E., Miyasaka, T., Launey, T., Chui, D.-H., Tanemura, K., Sato, S., Murayama, O., Ishiguro, K., Tatebayashi, Y., & Takashima, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5561-03.2004 · Cited by 261
Engel, T., Hernández, F., Avila, J., & Lucas, J. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0604-06.2006 · Cited by 260
Salkovic-Petrisic, M., & Hoyer, S. (2007) · Neuropsychiatric Disorders An Integrative Approach · doi:10.1007/978-3-211-73574-9_28 · Cited by 247
Sontag, E., Luangpirom, A., Hladik, C., Mudrak, I., Ogris, E., Speciale, S., & White, C. L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.4.287 · Cited by 228
Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments
Ksiezak-Reding, H., Liu, W.-K., & Yen, S.-H. (1992) · Brain Research · doi:10.1016/0006-8993(92)91476-u · Cited by 225
Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223
Tau alteration and neuronal degeneration in tauopathies: mechanisms and models
Brandt, R., Hundelt, M., & Shahani, N. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.018 · Cited by 221
Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice
Ikegami, S. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00964-7 · Cited by 221
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice
Le Corre, S., Klafki, H. W., Plesnila, N., Hübinger, G., Obermeier, A., Sahagún, H., Monse, B., Seneci, P., Lewis, J., Eriksen, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602913103 · Cited by 221
Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer’s disease
Tanimukai, H., Grundke-Iqbal, I., & Iqbal, K. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62486-8 · Cited by 220
Self-citationLefebvre, T., Ferreira, S., Dupont-Wallois, L., Bussière, T., Dupire, M.-J., Delacourte, A., Michalski, J.-C., & Caillet-Boudin, M.-L. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00477-4 · Cited by 209
Liu, F., Li, B., Tung, E., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05955.x · Cited by 208
Self-citationPolymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity
Alonso, A. D. C., Li, B., Grundke-Iqbal, I., & Iqbal, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603214103 · Cited by 206
Self-citationAxonal Transport Rates In Vivo Are Unaffected by Tau Deletion or Overexpression in Mice
Yuan, A., Kumar, A., Peterhoff, C., Duff, K., & Nixon, R. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5242-07.2008 · Cited by 190
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model
Pérez, M., Hernández, F., Lim, F., Díaz-Nido, J., & Avila, J. (2003) · Journal of Alzheimer's Disease · doi:10.3233/jad-2003-5405 · Cited by 180
Hoyer, S. (2004) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-8969-7_8 · Cited by 174
Li, M., Makkinje, A., & Damuni, Z. (1996) · Biochemistry · doi:10.1021/bi960581y · Cited by 174
Goedert, M., Jakes, R., Qi, Z., Wang, J. H., & Cohen, P. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65062804.x · Cited by 171
Pseudophosphorylation of tau protein alters its ability for self‐aggregation
Haase, C., Stieler, J. T., Arendt, T., & Holzer, M. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02287.x · Cited by 169
Alzheimer's disease is a vasocognopathy: a new term to describe its nature
de La Torre, J. C. (2004) · Neurological Research · doi:10.1179/016164104225016254 · Cited by 167
Kenessey, A., & Yen, S.-H. C. (1993) · Brain Research · doi:10.1016/0006-8993(93)90478-6 · Cited by 166
Whitworth, G. E., Macauley, M. S., Stubbs, K. A., Dennis, R. J., Taylor, E. J., Davies, G. J., Greig, I. R., & Vocadlo, D. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja065697o · Cited by 165
Li, L., Sengupta, A., Haque, N., Grundke, I., & Iqbal, K. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.04.047 · Cited by 164
Self-citationCdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats
Wen, Y., Yang, S.-H., Liu, R., Perez, E. J., Brun-Zinkernagel, A. M., Koulen, P., & Simpkins, J. W. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.10.011 · Cited by 162
del C. Alonso, A., Zaidi, T., Novak, M., Barra, H. S., Grundke-Iqbal, I., & Iqbal, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105365200 · Cited by 160
Self-citationCalpain‐mediated degradation of p35 to p25 in postmortem human and rat brains
Taniguchi, S., Fujita, Y., Hayashi, S., Kakita, A., Takahashi, H., Murayama, S., Saido, T. C., Hisanaga, S., Iwatsubo, T., & Hasegawa, M. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02431-5 · Cited by 148
Glucose metabolism and Alzheimer's disease
Schubert, D. A. (2005) · Ageing Research Reviews · doi:10.1016/j.arr.2005.02.003 · Cited by 146
Wen, Y., Planel, E., Herman, M., Figueroa, H. Y., Wang, L., Liu, L., Lau, L.-F., Yu, W. H., & Duff, K. E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5245-07.2008 · Cited by 145
Tau Therapeutic Strategies for the Treatment of Alzheimers Disease
Churcher, I. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743057 · Cited by 144
Wang, J., Tung, Y. C., Wang, Y., Li, X., Iqbal, K., & Grundke, I. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02944-1 · Cited by 140
Self-citationMutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia
Stanford, P. M. (2003) · Brain · doi:10.1093/brain/awg090 · Cited by 136
Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease
Yanagisawa, M., Planel, E., Ishiguro, K., & Fujita, S. C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01480-5 · Cited by 134
Concurrent alterations of O‐GlcNAcylation and phosphorylation of tau in mouse brains during fasting
Li, X., Fen, L., Wang, J., & Gong, C. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04735.x · Cited by 130
Self-citationGong, C., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9101 · Cited by 128
Self-citationNakashima, H., Ishihara, T., Suguimoto, S. P., Yokota, O., Oshima, E., Kugo, A., Terada, S., Hamamura, T., Trojanowski, J. Q., Lee, V. M. ‐., et al. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1087-4 · Cited by 122
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy
Sanbe, A., Osińska, H. E., Villa, C. R., Gulick, J. M., Klevitsky, R., Glabe, C. G., Kayed, R., & Robbins, J. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503324102 · Cited by 113
Zhang, M., Li, J., Chakrabarty, P., Bu, B., & Vincent, I. J. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63347-0 · Cited by 110
GSK-3 inhibitors for Alzheimer’s disease
Ávila, J., & Hernández, F. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11.1527 · Cited by 106
The potential role of tau protein O-glycosylation in Alzheimer's disease
Robertson, L. A., Moya, K. L., & Breen, K. C. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6505 · Cited by 99
Tandon, A., Yu, W. H., Wang, L., Rogaeva, E. A., Sato, C., Chishti, M. A., Kawarai, T., Hasegawa, H., Chen, F., Davies, P., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01865.x · Cited by 90
Deng, Y., Li, B., Liu, F., Iqbal, K., Grundke, I., Brandt, R., & Gong, C. (2007) · The FASEB Journal · doi:10.1096/fj.07-8309com · Cited by 88
Self-citationTsujio, I., Zaidi, T., Xu, J., Kotula, L., Grundke-Iqbal, I., & Iqbal, K. (2005) · FEBS Letters · doi:10.1016/j.febslet.2004.11.097 · Cited by 80
Self-citationGarver, T. D., Harris, K. A., Lehman, R. A. W., Lee, V., Trojanowski, J., & Billingsley, M. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63062279.x · Cited by 80
p25 protein in neurodegeneration
Yoo, B. C., & Lübec, G. (2001) · Nature · doi:10.1038/35081146 · Cited by 79
Dynamic Nuclear and Cytoplasmic Glycosylation: Enzymes of O-GlcNAc Cycling
Iyer, S. P. N., & Hart, G. W. (2003) · Biochemistry · doi:10.1021/bi020685a · Cited by 79
Wang, D., Ling, Z.-Q., Cao, F., Zhu, L., & Wang, J. (2004) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00130.x · Cited by 79
Zhu, L., Wang, S. H., Ling, Z.-Q., Wang, D. L., & Wang, J. (2004) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00136.x · Cited by 77
Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Huang, H., & Klein, P. S. (2006) · Current Drug Targets · doi:10.2174/1389450110607011389 · Cited by 76
Ulloa, L., de Garcini, E. M., Gómez‐Ramos, P., Morán, M. A., & Ávila, J. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90081-7 · Cited by 75
Effect of melatonin on calyculin A-induced tau hyperphosphorylation
Li, X., Wang, X., Zhang, J., Wang, Q., & Wang, J. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.01.023 · Cited by 68
Künzi, V., Glatzel, M., Nakano, M. Y., Greber, U. F., LEUVEN, F. V., & Aguzzi, A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-17-07471.2002 · Cited by 67
Post-translational modifications of tau protein
Pevalova, M., Filipčík, P., Novák, M., Ávila, J., & Iqbal, K. (2006) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/bf03656852 · Cited by 64
Self-citationTissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat
Vita, M. F., Abdel‐Rehim, M., Olofsson, S., Hassan, Z., Meurling, L., Sidén, Å., Sidén, M., Pettersson, T., & Hassan, M. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.02.001 · Cited by 61
Pharmacological Management of Neurological and Psychiatric Disorders
Enna, S. J., & Coyle, J. T. (1998) · Cited by 57
Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now
Lee, V. M. ‐., & Trojanowski, J. Q. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s328 · Cited by 55
Li, S. P., Deng, Y., Wang, X. C., Wang, Y. P., & Wang, J. (2004) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00116.x · Cited by 49
d’Abramo, C., Ricciarelli, R., Pronzato, M. A., & Davies, P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03931.x · Cited by 49
Developing pharmacological therapies for Alzheimer disease
Iqbal, K., & Grundke, I. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7221-9 · Cited by 46
Self-citationPeptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5
Kesavapany, S., Zheng, Y., Amin, N. D., & Pant, H. C. (2007) · Biotechnology Journal · doi:10.1002/biot.200700057 · Cited by 34
Structure-Based Approaches in the Design of GSK-3 Selective Inhibitors
Patel, D. S., Dessalew, N., Iqbal, P., & Bharatam, P. V. (2007) · Current Protein and Peptide Science · doi:10.2174/138920307781369409 · Cited by 32
A pool of β‐tubulin is hyperphosphorylated at serine residues in Alzheimer disease brain
Vijayan, S., El-Akkad, E., Grundke, I., & Iqbal, K. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03201-x · Cited by 28
Self-citationControversies over p25 in Alzheimer's disease
Nguyen, K. C., Rosales, J. L., Barboza, M., & Lee, K. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4207 · Cited by 26
Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease
Roder, H. M., & Hutton, M. L. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.435 · Cited by 22
Pallàs, M., Verdaguer, E., Jordà, E. G., Jiménez, A., Canudas, A. M., & Camins, A. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.03.047 · Cited by 21
Utton, M. A., Gibb, G., Burdett, I. D. J., Anderton, B. H., & Vandecandelaere, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011384200 · Cited by 20
Treating the Lesions, Not the Disease
Zhu, X., Ávila, J., Perry, G. L., & Smith, M. A. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070193 · Cited by 13
Cited by
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Metals, oxidative stress and neurodegenerative disorders
Jomova, K., Vondrakova, D., Lawson, M., & Valko, M. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0563-x · Cited by 1,052
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Post-translational modifications of tau protein: Implications for Alzheimer's disease
Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 641
Metadata
- Authors
- Gong, C.-X., & Iqbal, K.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-10-01
- Volume
- 15
- Issue
- 23
- Pages
- 2321-2328
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2011485908
- Cited by
- 644
- References
- 140
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.